Ovid will discontinue development of OV101 (**oxadol), a delta (δ-selective **AA receptor agonist, in Angelman syndrome. Furthermore, Ovid does not plan to initiate further clinical studies of OV101 in Fragile X syndrome
https://investors.ovidrx.com/news-r...s-update-ov101-program-and-prioritization-its
- Forums
- ASX - By Stock
- NEU
- OVID FAIL
OVID FAIL, page-9
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.65 |
Change
-0.540(2.81%) |
Mkt cap ! $2.383B |
Open | High | Low | Value | Volume |
$18.98 | $19.15 | $18.50 | $10.51M | 560.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | $18.62 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.65 | 1127 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 810 | 18.530 |
4 | 1225 | 18.510 |
7 | 2678 | 18.500 |
2 | 1169 | 18.490 |
1 | 162 | 18.450 |
Price($) | Vol. | No. |
---|---|---|
19.080 | 300 | 1 |
19.150 | 150 | 1 |
19.200 | 899 | 2 |
19.240 | 550 | 1 |
19.340 | 1000 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
NEU (ASX) Chart |